A research collaboration to tackle gastrointestinal disorders that have their roots in the central nervous system.

Takeda

Cerevance

An exclusive license agreement and research agreement to develop cord blood-derived chimeric antigen receptor-directed natural killer (CAR NK)-cell therapies, ‘armored’ with IL-15, for the treatment of B-cell malignancies and other cancers.

Novel therapies to reboot cells and organs

Cell & Gene Therapy

The University of Texas M.D. Anderson Cancer Center

Chimeric antigen receptor T-cell (CAR-T) therapy involves genetically engineering T cells to target and kill cancer cells

To discover, develop, and commercialize novel therapies for inflammatory bowel disease (IBD).

Prometheus Biosciences

Under the terms of the T-CiRA agreement, Takeda has the global rights to develop and commercialize the iCART product and CiRA will receive development and approval milestones.

Center for iPS Cell Research and Application, Kyoto University

The acquisition makes Takeda's geographic footprint and leading position in Japan and the U.S., bringing its highly-innovative medicines to approximately 80 countries/regions

Shire

Leveraging personal data for custom-fit diagnosis and treatment

Precision Medicine

<div>
 
 Mersana Therapeutics is a clinical-stage biopharmaceutical company that discovers and develops novel antibody-drug conjugates (ADC) to treat cancer. It uses its proprietary ADC platforms to design, test, and advance its pipelines. It has four platforms: 1) DolaLock technology (with controlled bystander effect), 2) Dolaflexin (ability to carry multiple drug molecules), 3) Dolasynthen (ability to generate homogeneous ADCs), and 4) Immunosynthen (capable of inducing anti-tumor activity).
 
 
 Mersana&rsquo;s lead product candidate, upifitamab rilsodotin (UpRi), targeting NaPi2b, is undergoing trials to treat ovarian cancer and was in Phase III of clinical trials as of December 2022. In addition, it was developing two other ADC programs in clinical and preclinical studies: 1) XMT-2056, which is designed to treat HER2 (human epidermal growth factor receptor, which is a protein that promotes cancer growth and the company planned to initiate a Phase I trial during 2022, and 2) XMT-1660, which is designed to target B7-H4 to treat multiple solid tumors and is also in Phase I of clinical trials. In May 2022, the FDA granted an orphan drug designation to XMT-2056 for the treatment of patients with gastric cancers. Its collaboration with Asana Biosciences, ASN004, was in Phase 1 clinical trials targeting the 5T4 oncofetal antigen (trophoblast glycoprotein), which is expressed in a wide range of malignant tumors. The company also had four other undisclosed programs in preclinical studies and three programs in the discovery stage of the pipeline.
 
 
 Key customers and partnerships
 
 
 The company has several partners that are using its platforms to advance their ADC pipelines. In February 2022, the company signed a research collaboration and license agreement with Janssen Biotech to develop three ADC targets. Furthermore, 
 <a href="https://sp-edge.com/updates/12204">
 the company partnered with pharma giant GlaxoSmithKline 
 </a>
 (GSK) in August 2022&nbsp; to co-develop XMT-2026, receiving an initial payment of USD 100 million.&nbsp;
 
 
 Funding and financials
 
 
 The company began trading on Nasdaq in June 2017 under the ticker symbol &quot;MRSN,&quot; raising USD 75 million at its IPO. The company raised USD 174.8 million in June 2020 via a public offering consisting of 9.2 million shares priced at USD 19 per share. The new funds were used to advance XMT-1536 and XMT-1592 and for working capital, capital expenditures, and general expenses.
 
 
 For the six months ended June 2023, the company is yet to generate revenue from drug sales. However, collaboration revenue for the same period was USD 18.5 million, increasing by almost 2x YoY. The company&rsquo;s net loss increased by 11.1% YoY to USD 110.5 million for 1H 2023. Cash, cash equivalents and marketable securities as of June 30, 2023 were USD 286.6 million, compared to USD 280.7 million as of December 31, 2022. Mersana expects that its available funds will be sufficient to support its current operating plan commitments into 2026.
 
</div>

Cerevance is a clinical-stage biopharmaceutical company dedicated to advancing precision treatments for central nervous system (CNS) disorders. The company's core technology is its proprietary Nuclear Enriched Transcript Sort sequencing (NETSseq) platform, which isolates and analyzes specific cell populations from human post-mortem brain tissue samples. By leveraging a vast collection of over 14,000 brain tissue samples spanning various ages, brain regions, and disease states, Cerevance gains unprecedented insights into the gene expression profiles and biological pathways underlying CNS diseases. This enables the identification of novel therapeutic targets that traditional methods like animal models or stem cells cannot uncover.
Cerevance's lead program is CVN424, a first-in-class, non-dopaminergic oral therapy for Parkinson's disease. In March 2023, the company reported positive Phase two data, demonstrating significant dose-dependent reductions in off-time for Parkinson's patients treated with CVN424. Additionally, Cerevance is advancing CVN766, a selective orexin one receptor antagonist, and CVN293, a novel potassium efflux blocker targeting neuroinflammation, for conditions like schizophrenia, Alzheimer's disease, and amyotrophic lateral sclerosis (ALS).
In August 2022, Cerevance entered a multi-year strategic collaboration with Merck to leverage its NETSseq platform in identifying novel Alzheimer's disease targets. As part of this deal, Cerevance out-licensed one of its discovery-stage programs to Merck and is eligible to receive up to USD 1.1 billion in milestone payments, along with royalties on future product sales.

Cardurion Pharmaceuticals is a clinical-stage biotechnology company focused on developing novel therapeutics for cardiovascular diseases. Founded in 2017 and headquartered in Burlington, Massachusetts, with additional facilities in Shonan, Japan, Cardurion specializes in translating cardiovascular signaling pathways into groundbreaking treatments. The company's pipeline includes two lead drug candidates: CRD-750, a phosphodiesterase-9 (PDE9) inhibitor for heart failure, and CRD-4730, a Calcium/Calmodulin-dependent Protein Kinase II (CaMKII) inhibitor. As of July 2024, Cardurion was evaluating CRD-750 in two Phase 2 clinical trials involving 640 patients with heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF). The company was also conducting a Phase 2 trial of CRD-4730 for catecholaminergic polymorphic ventricular tachycardia (CPVT), a rare genetic arrhythmic disease. Cardurion acquired CRD-750 from Imara in 2022 for USD 34.75 million upfront, with potential additional payments of up to USD 60 million based on achieving certain milestones. The company's research efforts also include a TRPC6 inhibitor in preclinical studies. As of July 2024, Cardurion employed approximately 65 people, with 50 based in the US and 15 at its R&D facility in Japan.
Key customers and partnerships
Cardurion Pharmaceuticals has established partnerships with several organizations in the biotechnology and pharmaceutical industries. In August 2017, the company formed a partnership with Takeda Pharmaceuticals, which included the establishment of Cardurion's R&D facility in Shonan, Japan. Additionally, Cardurion has received investments from prominent firms such as Bain Capital Life Sciences, Bain Capital Private Equity, and Polaris Partners.

Targeting complex diseases with complex molecules

Large-molecule Therapeutics

<div>
 
 Avidity Biosciences is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs). Their proprietary AOC platform combines the specificity of monoclonal antibodies with the precision of oligonucleotide therapies, enabling targeted delivery of RNA therapies to address diseases previously unreachable with existing approaches.
 
 
 
 
 Avidity's lead product candidate, delpacibart etedesiran (AOC 1001), is an investigational treatment designed to address the root cause of myotonic dystrophy type one (DM1) by reducing levels of disease-related DMPK mRNA. In May 2024, AOC 1001 received Breakthrough Therapy designation from the FDA for the treatment of DM1. Avidity is initiating the global Phase 3 HARBOR study of AOC 1001 this quarter, with primary endpoints including video hand opening time and key secondary endpoints evaluating muscle strength and activities of daily living. Previous data demonstrated reversal of disease progression across multiple functional measures when compared to natural history data.
 
 
 
 
 Beyond DM1, Avidity's pipeline includes clinical programs for Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical programs in muscle atrophy and Pompe disease. The company is also expanding into cardiology and immunology indications through internal efforts and partnerships, such as collaborations with Bristol Myers Squibb and Eli Lilly.
 
 
 
 
 In June 2024, Avidity completed an upsized public offering of common stock, raising approximately USD 461 million in gross proceeds to fund development of its clinical programs and advance research on the AOC platform.
 
</div>

Reach Out Cameroon is a non profit organisation aim is to improve the lives of the most vulnerable people  using a community-centred approach.

Bulungula Incubator aims to sustainably end poverty in a generation while enhancing community life and cohesiveness.

VillageReach is an international NGO headquartered in Seattle, WA with field offices located in Malawi and Mozambique, Africa. Through collaboration with public and private sector partners, VillageReach seeks to increase access to quality healthcare for the world most underserved communities, bringing life-saving innovations to scale and sustainability. VillageReach develops, tests and implements solutions that uniquely address barriers at the lower levels or last mile of healthcare delivery in low-resource communities including medicine availability, human resource constraints, data visibility and lack of infrastructure.

PSI provides life-saving information, products, and services to tackle some of the world’s most pressing health problems so that people can lead healthier, happier, and more productive lives.

Seed Global Health strengthens health education and delivery in places facing a dire shortage of health professionals by working with partner countries to meet their long-term health care human resource needs.

Ascentage Pharma develops novel small-molecule therapies for cancer, hepatitis B, and age-related diseases. They have developed a pipeline of seven drug candidates that disrupt complex and difficult-to-target protein-protein interactions and are next-generation tyrosine kinase inhibitors.

Crescendo Biologics is a new Cambridge-based company whose vision is to deliver next-generation antibody therapeutics based on novel class-leading platforms.  The focus of the company is on developing platforms that will address key issues in generating high-affinity, soluble, human VH antibody fragments. These are the smallest fragments that retain antibody binding, and have many desirable properties as potential therapeutics. Crescendo will then utilise these platforms for product development of in-house targets or in partnership with other companies.

Red Sox Foundation is a Red Sox Nation power that improves health, educational, and recreational opportunities for kids, families, veterans, and communities in need. As part of their commitment to creating a good influence in their communities, Boston Red Sox Owner John Henry, Chairman Tom Werner, President/CEO Emeritus Larry Lucchino, and the team's partners formed and supported the Red Sox Foundation immediately after assuming ownership.

Boston Community Pediatrics is the first nonprofit private pediatric practice bringing equity to pediatric healthcare in Boston. BCP is a new model of innovative pediatric healthcare that addresses the social determinants of health within a relationship-driven framework.

Marthas Table is a provider of healthy food and education for children of all ages.

Atlanta Community Food Bank serves food pantries, community kitchens, childcare centers, night shelters, and senior centers. The donors are manufacturers, wholesalers, retailers, brokers, restaurants, food drives, farmers, and individuals.

The American Red Cross (ARC), also known as the American National Red Cross, is a humanitarian organization that provides emergency assistance, disaster relief, and education inside the United States. It is the designated U.S. affiliate of the International Federation of Red Cross and Red Crescent Societies. It is the largest single supplier of blood and blood products in the United States, collecting and processing approximately 40 percent of the blood supply and distributing it to about 2,600 hospitals and transfusion centers nationwide. The organization researches and tests to protect the safety of the blood supply. It was among the first to develop and implement testing for many infectious diseases including, HIV, hepatitis B and C viruses, West Nile virus, and Chagas disease. The ARC operates the nationwide hemovigilance program to examine donor and patient adverse reactions. Data from the program is used to enhance blood product quality and safety The ARC serves on key committees of AABB and other blood-related organizations, and works closely with the U.S. Food and Drug Administration (FDA). The American Red Cross was established in 1881 and is headquartered in Washington, District of Columbia with 39 immunohematology reference laboratories nationwide.

Urban Farming Institute is a learning facility offering integrative farming methods designed to improve indoor farming operations. It combines tested, patented technologies with expert support on a global scale, assisting urban farmers in the process of vertical farming and streamlining processes linked to indoor horticulture. To get people involved in growing food and creating a healthy community, it has as its aim to create and promote urban farming.

American Forests offers services to restore threatened forest ecosystems and inspire people to value and protect urban and wildland forests. Their projects have restored hundreds of thousands of acres of wildlife habitat, protected vital watersheds, and sequestered millions of tons of greenhouse gases. They are advocates for expanding urban tree canopy and green space, and a key funder of urban forest initiatives that have transformed communities across the country.

Out Teach provides professional development for elementary school teachers.

Greater Chicago Food Depository they programs includes food pantries, soup kitchens, and shelters,

Food For Free improves access to healthy food through establishing innovative programming and partnerships to overcome barriers and strengthen the community food system.

Georgia Organics invests in organic farmers and community allies to cultivate a resilient, local food movement.

Acumen is a nonprofit venture fund that invests in early-stage companies bringing critical services like agriculture, clean energy, education, financial inclusion, healthcare and workforce development to low-income communities in 14 countries across East and West Africa, South Asia, Latin America, and the United States.  Since 2001, Acumen invested $128 million in 128 companies that have transformed the lives of over 308 million low-income people.

San Diego River Park Foundation is a  nonprofit organization created in 2001 to improve the future of the historic San Diego River, as well as the residents of San Diego and its visitors.

Common Threads offers psychotherapy, occupational therapy, and alternative school placement. Their purpose is to empower people with autism, mental health issues, and sensory challenges by providing them and their families with real assistance. They achieve this by providing a range of evidence-based, personalized therapeutic and educational programmes that are tailored to an individual's strengths, needs, and aspirations.

Mama's Kitchen aims to offer nutritional assistance to San Diego individuals at risk of undernourishment because of serious conditions like HIV, cancer, congestive heart failure, type 2 diabetes, and chronic renal disease.

The only focused effort of its kind, Project Scientist was developed to offer girls the essential support unique to each stage of a future scientists' life serving girls/women ages 4 to PhD age. Through extensive research on current trends and practices has built a robust & focused, three-phase, program pipeline to serve as a national model for advancing girls and women, of all ages, in their STEM interests and passions.

Breakthrough Greater Boston transforms urban education for students and teachers through its unique Students Teaching Students model. Through six years of intensive, tuition-free out-of-school-time programming for traditionally underserved middle and high school students.

Ambys Medicines is a biotechnology company focused on discovering and developing regenerative and restorative therapies. Ambys Medicines is working to fundamentally transform the lives of people suffering from severe liver diseases by creating breakthrough therapies capable of restoring liver function, preventing the progression of liver disease, and treating the devastating complications of liver failure.

Cardurion Pharmaceuticals is a Boston-based biotechnology company focused on developing novel therapeutics for the treatment of heart failure and other cardiovascular diseases. The company is advancing groundbreaking clinical programs targeting PDE9 and CaMKII inhibition, leveraging its expertise in cardiovascular signaling pathways to address unmet patient needs.

Bridge Medicines is a drug discovery company launched in partnership with Memorial Sloan Kettering Cancer Center, The Rockefeller University, Weill Cornell Medicine, Takeda Pharmaceutical Company Ltd. and healthcare investment firms Bay City Capital and Deerfield Management. Bridge Medicines is a groundbreaking initiative that completes an unbroken, fully funded and professionally staffed path from concept to drug candidate, to develop efficiently and quickly innovative therapeutics for the treatment of human diseases.

xFOREST Therapeutics provides technology platforms that integrate massively parallel biochemical analysis systems for species of RNA structures and in silico analysis pipelines. Their analyses include various RNA structures, regardless of their source organ, species, or virus.

Enterome’s OncoMimic technology allows the overcoming of immune tolerance against cancer cells, with broad applicability against solid tumor via an off-the-shelf, easy to manufacture technology. Enterome’s potentially first-in-class small protein and peptide drug candidates modulate the immune system by closely mimicking the structure, effect or actions of Tumor Associated Antigens to induce a potent, endogenous CD8 T cell response.  The company’s most advanced programs are in Phase 2 clinical trials in hard-to-treat tumors such as glioblastoma, adrenal malignancies and colorectal cancer.

Turnstone Biologics is a privately-held clinical-stage biotech company. Turnstone Biologics’ mission is to deliver breakthrough cancer immunotherapies by advancing two leading and complementary platforms targeting tumor immunity, to improve survival for people with cancer.

GEXVal is a research and development-oriented drug discovery company. The company specializes in the creation of treatments for rare and incurable diseases. The mission of GEXVal is to provide patients and families with the rare and incurable diseases with innovative, cost-effective treatment options that will enhance their health and quality of life.

Reborna Biosciences  provides research and development in the field of genetic diseases. The company develops therapeutic options for area of unmet medical needs in genetic rare disease. The company's technology enables low-molecular compounds to target ribonucleic acid. The company provides new disease-modifying drugs for patients suffering from rare genetic diseases including spinal muscular atrophy.

FIMECS is a protein degradation technology-based drug discovery biotech focused on developing first-in-class protein degradation therapeutics for cancers and other difficult-to-treat diseases. The human body is comprised of at least 18,097 proteins.It has been revealed that 1,500 of them are related to certain diseases, nevertheless only about 300 proteins have been regarded as druggable targets by small molecule drug discovery and all the rest have been undruggable.

Cerevance is a biotechnology company that develops novel therapeutics for neurological diseases, including chronic neurodegenerative conditions such as Alzheimer's disease, Parkinson's disease, frontotemporal dementia, and amyotrophic lateral sclerosis. Using a large and growing repository of over 15,000 human brain tissue samples, the company generates an unprecedented level of expression and epigenetic data, enabling the company to identify the most promising targets for the next generation of treatments for CNS disorders.

Chordia Therapeutics is a research and development type bioventure specializing in oncology field. The company has a mission of delivering new therapeutic drugs to patients as soon as possible in the area of ​​cancer with high unmet medical need.

Neurymune Biotech Co., Ltd. is a national cancer research center specializing in the development of cancer immunotherapies based on CAR-T cell therapy and a venture company from Yamaguchi University. They aim to be a leading company responsible for the next generation in the field of cancer immunotherapy.

Molecular Templates is a clinical-stage biopharmaceutical company developing therapeutic compounds for cancer and other serious diseases. It primarily develops a pipeline of therapies through its proprietary biologic-engineered toxin body (ETB) drug platform with unique mechanisms of action which are highly differentiated from antibody-drug conjugates (ADCs).

Scohia Pharma is a biotech venture that will have both substantial research and development resources and be nimble enough to make decisions quickly, will strive to improve patient quality of life by providing patients and healthcare professionals with new therapeutic medications for renal, metabolic.

Helpmum offers mobile healthcare services. They use the power of mobile technology and low-cost innovation to tackle maternal and infant mortality in remote areas. HelpMum offers clean birth kits to women in underprivileged and underserved areas and uses its vaccination tracker and HelpMum adviser to make sure that babies don't miss their vaccination appointments. With the help of mobile technology and low-cost innovation, HelpMum aims to reduce maternal and infant mortality in Nigeria.

PvP Biologics is developing an oral enzyme for the treatment of celiac disease. Our mission is to develop a highly-effective therapeutic product to reduce the burden of living with this disease. Towards this end, we are advancing a product candidate designed to break down the immuno-reactive parts of gluten in the stomach and thereby avoid the painful symptoms and damage done in the small intestine from accidental gluten ingestion.

Avidity Biosciences, Inc. is pioneering a new class of oligonucleotide-based therapies called AOCs designed to overcome the current limitations of oligonucleotide therapies in order to treat a wide range of serious diseases. Avidity utilizes its proprietary AOC platform to design, engineer and develop therapeutics that combine the tissue selectivity of monoclonal antibodies and the precision of oligonucleotide therapies in order to access previously undruggable tissue and cell types and more effectively target underlying genetic drivers of diseases. Avidity's lead product candidate, AOC 1001, is designed to treat myotonic dystrophy type 1, and its four other muscle programs are focused on the treatment of muscle atrophy, Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy and Pompe disease. In addition to its muscle franchise, Avidity has development efforts focused on immune and other cell types.

Maverick Therapeutics is a biotech company focused on improving the lives of patients with solid tumor cancers by developing breakthrough T cell immunotherapies with improved safety and efficacy. Their highly innovative platform, COBRA™, is the most advanced bispecific T cell engaging platform in its class, designed to safely target solid tumors with highly specific and potent activity.

Elliegrid provides medication management services which helps organize pills, set reminders, and track compliance. The company offers pill-box design and software data analytics solutions which also provide healthcare professionals and caregivers with real-time compliance data of their patients and loved ones, so they can make timely interventions.  Elliegrid was founded by Hieu Nguyen, Regina Vatterott, Nicolas Dhanam, and Abe Matamoros in 2015 and is based in Austin, Texas.

Mersana Therapeutics employs its biodegradable polymer platform to create new and better medicines. They are advancing their own clinical-stage pipeline of novel compounds with the potential to address multiple oncology indications.  It was founded in 2005 and headquartered in Cambridge, Massachusetts.

Ultragenyx Pharmaceutical develops therapeutics for rare diseases, sometimes referred to as Orphan products. Ultragenyx  is a efficient and effective development strategies are essential for success in the rare disease space, in which information may be incomplete or ambiguous, and few development precedents exist. The management team's experience in selecting and developing products with clear mechanisms of action for untreated rare diseases will help Ultragenyx create life-changing therapeutics by leveraging existing yet undeveloped science for these little-known indications.

At Outpost, they are committed to developing novel therapeutics for the treatment of gastrointestinal and urologic disorders.  The company's lead clinical-stage product candidate is in development for the treatment of overactive bladder (OAB) and irritable bowel syndrome (IBS).

Aquinnah Pharmaceuticals is focused on an exciting new area of research and development to modulate neurodegenerative stress granules, believed to be important in the pathology of amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease.

Naurex Inc. is a clinical-stage company developing novel therapies for depression and other CNS disorders based on a new mechanism of action for modulating the N-methyl-D-aspartic acid receptor (NMDAR). Using these discoveries, Naurex researchers have generated novel chemical drug classes known as glycine-site functional partial agonists (GFPAs), which modulate the receptor in a different way than existing NMDAR agents. The company's drug development programs based on its GFPA NMDAR modulators include the first-generation molecule, GLYX-13, the second-generation NRX-1050 small molecule series and additional compounds from Naurex's platform of novel NMDAR modulators.

Seattle Genetics is a clinical-stage biotechnology company that focuses on developing and commercializing monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases. Its lead product, SGN-35, is in the pivotal trial for patients with relapsed or refractory Hodgkin lymphoma. The company's other product candidates in various stages of clinical trials include dacetuzumab (SGN-40), a humanized anti-CD40 antibody; lintuzumab (SGN-33), a humanized anti-CD33 antibody; SGN-70, a humanized anti-CD70 antibody for the treatment of autoimmune diseases; SGN-75, which is in Phase I clinical trials for metastatic renal cell carcinoma and non-Hodgkin lymphoma; ASG-5ME, a preclinical antibody-drug conjugate product candidate for the treatment of solid tumors; and SGN-19A, a preclinical antibody-drug conjugate product candidate for the treatment of hematologic malignancies. It has collaborations with Bayer Pharmaceuticals Corporation; Celldex Therapeutics, Inc.; Daiichi Sankyo Co., Ltd.; Genentech; GlaxoSmithKline LLC; MedImmune, Inc.; Millennium; PSMA Development Company LLC; and Genmab A/S. The company also has an antibody-drug conjugates co-development agreement with Agensys, Inc.  The company was founded in 1997 and is headquartered in Bothell, Washington.

Alnylam is the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare genetic, cardio-metabolic, hepatic infectious, and central nervous system (CNS)/ocular diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of severe and debilitating diseases.

Xenon Pharmaceuticals is a biopharmaceutical company focused on the development of novel medicines through the application of our proprietary discovery platform, which we refer to as Extreme Genetics. Our product candidates are based on genetic insights derived from our research of families where individuals exhibit severe traits or phenotypes. They apply their expertise to predict which phenotypes are caused by single-gene defects. By identifying and characterizing the single-gene defects responsible for such severe phenotypes, they gain valuable insights into their function in human biology and their potential as drug targets. Given that these targets are often involved in diseases beyond the rare genetic disorders in which they are first identified, they are developing proprietary product candidates to treat both orphans as well as more prevalent diseases

BioNumerik Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of drugs that help in the treatment of cancer. The company’s two oncology drug candidates, Tavocept and BNP1350, are in late-stage clinical development. BioNumerik Pharmaceuticals, Inc. was founded in 1992 and is based in San Antonio, Texas.

Takeda researches, develops, manufactures, sells, markets, imports, and exports pharmaceutical drugs. They offer pharmaceuticals, therapeutics, oncology, and gastroenterology vaccines.

<div> Takeda (NYSE: TAK) is a Japanese R&amp;D-driven pharmaceutical company that discovers and delivers life-transforming treatments. It has been listed on the Tokyo and Osaka stock exchanges since 1949. In 2018, Takeda was listed on the New York Stock Exchange, being the only pharmaceutical company listed on both the TSE and NYSE. In <a href="https://www.takeda.com/newsroom/newsreleases/2019/takeda-completes-acquisition-of-shire-becoming-a-global-values-based-rd-driven-biopharmaceutical-leader/"> January 2019 </a> , the company completed the acquisition of Shire and achieved global R&amp;D-driven biopharmaceutical leadership with an operational presence in ~80 countries and regions. Takeda claims to be the leader for several decades in treating rare hematology and innovation of plasma solutions and is one of the <a href="https://www.takeda.com/science/areas-of-focus/pdt/"> top three plasma </a> organizations in the world, offering the complete life cycle from donor to patient. Takeda generated revenue of JPY 4,027.5 billion (~USD 28.3 billion) in FY2023 (ended March 31). Takeda&rsquo;s Gastrointestinal (GI) segment (~27% of total revenue in FY2023) focuses on providing innovative therapeutics for patients suffering from GI and other inflammatory diseases. Rare diseases (~18%) consists of treatments for rare diseases in hematology and hemostasis, immunology, and metabolic. The company&rsquo;s Plasma-Derived Therapies (PDT) segment (~17%) offers sustainable plasma solutions to treat patients with diseases such as immunodeficiencies and neuroimmunology and other chronic diseases. Takeda&rsquo;s Neuroscience (~16%) segment provides solutions to treat patients with neurologic diseases and also includes patient awareness and education services. The relatively small Oncology (~11%) segment comprises innovative solutions to treat cancer patients. Takeda also offers vaccines to treat common spreads and challenging infectious diseases such as dengue and COVID-19. Takeda had three research sites and more than 25 manufacturing sites as of FY2023. The US is Takeda&rsquo;s largest market, accounting for ~52% of total revenue (FY2023), followed by the Europe and Canada segment (~21%). Japan as a single market made up ~13% of FY2023 revenue. Takeda expects FY2024 revenue growth to be negative 4.7% (12.8% YoY in FY2023) due to the loss of sales from two key medicines: VYVANSE and AZILVA and lower coronavirus vaccine revenue. Takade plans to achieve net-zero greenhouse gas (GHG) emissions across all operations by 2040. </div>

Takeda enhances patient care for rare genetic disorder in the UAE and beyond

Companies providing genetic tests to identify individuals with high risk or at-risk of having hereditary disease, aid physicians with a diagnosis, and support clinical decision making.

Secure cloud-based platforms and data sharing networks that collect, index, store, and analyze large amounts of health data and patient population data sets from sources including genomic, clinical, wearables, imaging, and population data.

Biopharma and biotechnology companies that develop precision medicine drugs based on novel disease biomarkers present in multi-omic patient population data and genetic insights.

Companies that study intergenomic variations in genes associated with drug response and metabolism to match patients with the appropriate drug and dosage.

Companies that develop an in-vitro medical device or imaging tools and tests that identify genetic mutations for both diagnostic (nature of the disease) and prognostic (likely course of the disease) purposes, allowing providers to match a patient to a specific drug or therapy.

Software analytics platforms that integrate multiple omics datasets (genomics, transcriptomics, proteomics, and metabolomics) to gain insights and support target discovery, drug development, clinical trials, and diagnostics.

Artificial intelligence is identifying and testing new therapies faster than ever.

AI Drug Discovery

INCUMBENTS_PRESENT

PROMINENT_CATEGORY

<div>
 
 Firefly Neuroscience, a biotech company that specializes in AI-driven neurological solutions, has made significant advancements in its Brain Network Analytics (BNA) technology, developed in collaboration with pharmaceutical companies Takeda and Novartis. The AI-powered BNA technology aims to provide objective measurement tools for neuroscience drug development.
 The technology is created using AI and Machine Learning (ML) based on Firefly's proprietary database of high-definition longitudinal electroencephalograms (EEG). The BNA technology offers a deep understanding of brain functionality, assisting in the diagnosis of mental and cognitive disorders and identifying the most effective therapy or drug for optimum patient treatment outcome.
 Firefly Neuroscience is primarily focused on developing AI-powered solutions to enhance patient outcomes for those suffering from mental health issues and neurological disorders. The key product of the company, the BNA platform, is a cloud-based, AI-enabled system. This platform is specially designed to objectively evaluate brain function by using cutting-edge AI and ML algorithms to analyze EEG data, both at rest and during activity.

</div>

Takeda

Featured Industries

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless